Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2026
Principal Office: San Diego, California
Context: The filing discloses the initiation of legal proceedings regarding the commercialization of the Company's product, Deramiocel, for Duchenne Muscular Dystrophy.
Key Financial Metrics
This Form 8-K is a disclosure of a material event and does not contain financial statements. The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Legal Action Filed: On May 7, 2026, Capricor filed a Complaint for Equitable Relief and Application for Preliminary Injunction in the Superior Court of New Jersey, Chancery Division, Bergen County.
- Defendants: Nippon Shinyaku Co., Ltd. and its U.S. subsidiary, NS Pharma (collectively "NS").
- Subject Agreement: The Commercialization and Distribution Agreement dated January 24, 2022 (the "U.S. Distribution Agreement").
- Allegations:
- A fundamental pricing flaw exists within the U.S. Distribution Agreement.
- NS failed to adequately prepare for the commercial launch of Deramiocel in the United States.
- NS has materially breached the terms of the agreement.
- Relief Sought:
- Rescission of the U.S. Distribution Agreement.
- Declaratory judgment granting Capricor the right to distribute Deramiocel directly or through other distributors.
- Preliminary injunctive relief and other equitable remedies.
Guidance, Outlook, and Risks
Management Commentary: The Company states the lawsuit is intended to protect patient access to Deramiocel. The filing includes a press release titled "Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy."
Risks and Contingencies:
- The filing contains forward-looking statements regarding the Complaint and its potential outcome.
- Actual results may differ materially due to risks associated with the litigation and other uncertainties.
- The Company explicitly states it undertakes no obligation to update or revise forward-looking statements.
- Investors are directed to review the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, for a comprehensive list of risks.
Investor Verification Checklist
- Verify the specific terms of the January 24, 2022, Commercialization and Distribution Agreement with Nippon Shinyaku.
- Review the attached Complaint for Equitable Relief (Exhibit 99.2) for detailed legal arguments regarding the alleged pricing flaw and breach of contract.
- Assess the current status of Deramiocel's commercial launch preparations in the U.S. market.
- Monitor subsequent filings for updates on the preliminary injunction application and the court's response.
- Review the Company's most recent Form 10-K (fiscal year ended December 31, 2025) for historical financial context and existing risk factors.